How to Plan and Run a Real-World Evidence Study, and How to Choose a CRO

How to Plan and Run a Real-World Evidence Study, and How to Choose a CRO

AUTHOR

Dragan | Co-Founder & CTO

A real-world evidence (RWE) study answers a question about how a medicine or a medical device performs in routine care. It uses real-world data (RWD): data from everyday practice, such as health records, registries and what patients report themselves, rather than only data from a randomized controlled trial. What RWE and RWD are, and why they matter, is covered in our overview of RWE in clinical trials. This guide is the practical part: how to plan and run an RWE study, and what to ask a CRO before you sign.

An RWE Study in Six Steps

1. Start With the Decision, Not With the Data

Every RWE study supports a decision. Typical ones are a regulatory submission or a label change, a post-authorization safety study, a benefit assessment for pricing and reimbursement, post-market clinical follow-up (PMCF) for a medical device, or a medical affairs question such as how a treatment is used in practice.

The decision sets how strong the evidence must be. A study meant for a regulator should have a protocol, a statistical analysis plan and traceable data from day one. A study for internal planning can be lighter. Write the research question in one sentence, with the population, the treatment or device, the outcome and the time frame. If it does not fit in one sentence, the study is not ready to plan.

2. Choose the Design: New Data, Existing Data, or Both

ApproachWhat it meansFits when
Prospective non-interventional studyPatients are treated as in routine care; sites and patients record the data during the study.You need outcomes that existing sources do not record, such as quality of life or other patient-reported outcomes.
Study of existing dataHealth records, claims data or registries are analyzed after the fact.The data already exists in sufficient quality, and speed matters.
Hybrid studyExisting data plus new collection, for example health records plus ePRO questionnaires.Existing sources answer part of the question, but not all of it.
Pragmatic trialPatients are randomized, but treated in routine care settings.You need a randomized comparison under real conditions. Check early which rules apply: randomizing patients goes beyond routine care.

A prospective study takes longer, but you decide what is collected. A study of existing data is faster, but limited to what was recorded, and that is often less than the question needs: the dose, the reason a treatment was stopped, or how the patient feels.

3. Check the Regulatory Route Before the Protocol Is Final

Whether a study counts as non-interventional decides which rules apply. For studies of medicines in the EU, a non-interventional study is a clinical study that is not a clinical trial (Article 2(2)(4) of Regulation (EU) No 536/2014). Check early whether your design still counts as non-interventional. If it does not, a study of a medicine may be a clinical trial, with its own approval process. Beyond that, check these points early:

This is an overview, not legal advice. Have your regulatory affairs team or the CRO confirm the route for each country before the protocol is final.

4. Make the Data Fit for Purpose

Two qualities matter most: is the data relevant to the research question, and is it reliable? The US FDA’s guidance on health records and claims data (final since July 2024) counts accuracy, completeness and traceability as reliability, and the availability of the key study variables and enough representative patients as relevance. In practice, check these points before the study starts:

5. Keep Sites and Patients in the Study

In most real-world and late-phase studies, data still reaches the eCRF by hand: typed in from paper, PDFs, health records or other clinical documents. That costs sites time, and sites in observational studies are paid less than in interventional ones. The less manual work a study asks for, the more likely sites are to keep recruiting and documenting.

6. Follow the Data While the Study Runs

An RWE study that is only analyzed at the end finds its problems too late. Track recruitment, questionnaire compliance and missing values per site from the first patient, so you can act while there is still time. Real-time dashboards show recruitment, compliance and selected parameters across visits and sites. Keep these views descriptive, and set out in the statistical analysis plan which interim analyses are planned.

How to Choose a CRO for an RWE Study

Many sponsors run RWE studies with a CRO. These questions help you compare CROs:

Some sponsors run RWE studies with their own team on a study platform instead, or split the work: the CRO runs the sites, the sponsor keeps the platform. Ask early which model the CRO supports. Not sure which CRO fits your study? Ask us: we work with several CROs and can suggest partners that fit your study.

Common Mistakes

How Climedo Supports RWE Studies

Climedo runs surveys, direct-to-patient studies with eCOA and ePRO, and non-interventional studies such as post-approval, observational and registry studies on one platform, with EDC, source data verification and site management. CROs can run studies for several sponsors on it, with reusable templates and workflows. Climedo is aligned with ICH GCP (E6), GAMP 5, EU GMP Annex 11 and FDA 21 CFR Part 11. More on the RWE platform for sponsors and CROs.

Planning an RWE study? Book a demo.

Dragan | Co-Founder & CTO

Dragan | Co-Founder & CTO

Climedo

Digital health entrepreneur. Passionate about clean UX and travelling to exotic countries. Creates products with love at Climedo Health.

Envelope Icon

Stay Up to Date on Our Insights & Events!